Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 49 - Preparations for testing in vivo
Patents for A61K 49 - Preparations for testing in vivo (35,376)
12/2003
12/04/2003US20030226154 Pathophysiology associated with a single gene (MASS 1) mutation underlying the robust audiogenic seizure phenotype in frings mice
12/04/2003US20030225033 Heat stable colloidal iron oxides coated with reduced carbohydrates and uses thereof
12/04/2003US20030224007 A protective protein in the form of vaccine, containing a polypeptide from a pro-region of a cathepsin L protease obtained from excretory/secretory products of newly excysted juvenile stages of Fasciola hepatical
12/04/2003US20030223996 Analyzing the level of B lymphocte stimulator (BLyS) expression in a sample of an individual using antibodies, comparing the level of BLyS assayed in biological sample with a standard level of BLyS expresion in normal sample
12/04/2003US20030223994 Protein ligands comprising an immunoglobulin heavy chain variable (VH) domain and an immunoglobulin light chain variable (VL) domain, wherein the proteins bind a complex comprising an MHC and a peptide, do not substantially bind the
12/04/2003US20030223956 Macromers having a backbone comprising a polymeric backbone comprising units with a 1,2- diol or 1,3-diol structure, such as polyvinyl alcohol, and pendant chains bearing crosslinkable groups and other modifiers. When crosslinked, the macromers
12/04/2003US20030223935 Fluorescent membrane intercalating probes and methods for their use
12/04/2003US20030223934 Diagnostic method for determining the presence or absence of airborne contaminants. This involves applying a nasal topical application product for restricting the flow of airborne contaminants near human nasal passages to create a proximate
12/04/2003CA2486173A1 Cell delivery fluid for prevention of cell settling in delivery system
12/04/2003CA2480742A1 Tropane compounds
12/03/2003EP1366774A1 Bone cement and X-ray contrast agent and methods of manufacturing the same
12/03/2003EP1365805A2 Novel targeted compositions for diagnostic and therapeutic use
12/03/2003EP1365804A2 Histidine proline rich glycoprotein (hprg) as an anti-angiogenic and anti-tumor agent
12/03/2003CN1460099A Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
12/02/2003US6657104 Cell-based, and whole-animal-based assays for detecting substances having therapeutic activity toward cardiac hypertrophy.
12/02/2003US6656451 Indole compounds as novel dyes for organ function monitoring
12/02/2003US6656450 Macrocyclic magnetic resonance imaging contrast agents
12/02/2003US6656449 High throughput assay for angiogenesis, toxic activity and apoptosis using fish eggs
12/02/2003US6656448 Matrix metalloproteinase inhibitors
12/02/2003US6655931 Peristaltic compressors suitable for relaxation-free compression of polarized gas
12/02/2003CA2113901C Preparation of microparticles
12/02/2003CA2046904C Cd4 specific recombinant antibody
11/2003
11/27/2003WO2003097108A1 Medicinal formulation in particular for treating herniated invertebral discs
11/27/2003WO2003097107A2 Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
11/27/2003WO2003097104A1 Treatment and prevention of tissue damage
11/27/2003WO2003097074A1 Contrast medium for using in image-producing methods
11/27/2003WO2003097027A1 OIL-IN-WATER EMULSION OF l-MENTHOL
11/27/2003WO2003097026A1 Smooth muscle peristole inhibitor
11/27/2003WO2003096990A2 Protein cages for the delivery of medical imaging and therapy
11/27/2003WO2003096944A1 Methods and formulations for the delivery of pharmacologically active agents
11/27/2003WO2003096891A1 Method and apparatus for quantitatively evaluating a kidney
11/27/2003WO2003096808A1 Prevention or treatment of abnormal lipoprotein, cholestasis and atherosclerosis
11/27/2003WO2002057499A3 Mdr1 variants and methods for their use
11/27/2003US20030220563 Methods and apparatus for monitoring and quantifying the movement of fluid
11/27/2003US20030220483 Comprises fibroblast growth factor homologous factor- 1 (FHF-1) for disgnosing, prevention and treatment of neurodegenerative or neoplastic disorders
11/27/2003US20030220382 Amines such as 2-((2-N,N-di-n-pentylamino)-indan-5-yl)amino-5 -nitro-benzoic acid, administered for prophylaxis of Alzheimer's disease
11/27/2003US20030220325 Such as 1-(4-(phenylsulfonyl)-naphthyl)piperazine; for treating treating diseases related to 5-HT receptor; radiolabelling
11/27/2003US20030219768 Lung cancer therapeutics and diagnostics
11/27/2003US20030219441 Combined methods and compositions for coagulation and tumor treatment
11/27/2003US20030219385 Contrast agents for magnetic resonance imaging and methods related thereto
11/27/2003US20030219383 Intramolecularly-quenched near infrared fluorescent probes
11/27/2003US20030219381 Animal model for infection by an apicomplexan parasite
11/27/2003US20030219380 Indolinone drug; controlling cell differentiation, cell proliferation
11/27/2003US20030219378 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
11/27/2003US20030219375 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
11/27/2003CA2482458A1 Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
11/26/2003EP1364578A1 Schizophrenia-like mental disease model animal, method of constructing the same and use thereof
11/26/2003EP1364206A2 Rapid method for screening compounds for in vivo activity
11/26/2003EP1363618A1 Pharmaceutical composition for treating multiple sclerosis
11/26/2003EP1363538A2 Enhanced ultrasound detection with temperature dependent contrast agents
11/26/2003EP0871492B1 Mesothelium antigen and methods and kits for targeting it
11/26/2003CN1128638C Ultrasonic contrast medium and its preparing process
11/25/2003USRE38329 Contrast agents for magnetic resonance imaging
11/25/2003US6653299 Labelled factor XIIIa substrates
11/25/2003US6653135 Dynamic protein signature assay
11/25/2003US6653090 Fatty acid and lactate oxidation; triacylglycerol degradation; ischemia and reperfusion
11/25/2003US6652836 Method for viewing tumor tissue located within a body cavity
11/25/2003US6652835 Targeting multimeric imaging agents through multilocus binding
11/25/2003US6652834 Tensioactive properties, long lasting activity in the blood pool
11/25/2003US6652833 Functionalized active-nucleus complex sensor
11/25/2003US6652782 Multi-stage method for producing gas-filled microcapsules
11/25/2003US6651459 Hyperpolarization of a gas
11/25/2003CA2119145C Ferrite particles and therapeutic and diagnostic uses therefore
11/22/2003CA2428555A1 Contrast agent for use in imaging methods
11/20/2003WO2003095457A1 Adenosine a3 receptor modulators
11/20/2003WO2003094976A1 Lyophilized edible food incorporating a marker
11/20/2003WO2003094975A1 Mr-signal emitting coatings
11/20/2003WO2003094930A1 Embolization using degradable crosslinked hydrogels
11/20/2003WO2003094710A2 Medium for contrast enhancement use for ultrasonic, endoscopic and other medical examinations
11/20/2003WO2003065971A9 Non-myeloablative tolerogenic treatment with tyrphostins
11/20/2003WO2003036317A3 Optical pumping modules, polarized gas blending and dispensing systems, and automated polarized gas distribution systems
11/20/2003WO2003032866A3 Detection and treatment of intravascular lesions
11/20/2003WO2003000864A3 Nucleic acid-associated proteins
11/20/2003WO2002100443A3 Identifying tissue within the body using a fluorescent dye
11/20/2003WO2002095022A3 Sequence-specific dna binding compounds and their use in targeting telomeres and other dna sequences
11/20/2003WO2002038744A3 Proteases
11/20/2003US20030217379 Defective tyrosine phosphatase animal model for diagnosing and treating diabetes and eating disorders
11/20/2003US20030216638 Magnetic resonance imaging; measuring pressure; medical diagnosis; lipid shell containing magnetic particles
11/20/2003US20030216546 Genetically engineered fusion proteins for use in diagnosis and treatment of cancer, viral infections, autoimmune and alloimmune diseases
11/20/2003US20030216353 Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
11/20/2003US20030216320 Peptide-based multimeric targeted contrast agents
11/20/2003US20030216317 Protein having cell-recognizing activity and/or cytocidal activity
11/20/2003US20030216284 Photoactivated drug therapy
11/20/2003US20030215822 Comprises nucleotide sequences coding polypeptide for use in diagnosis, treatment and prevention of cell proliferative, autoimmune/inflammatory, cardiovascular, neurological and developmental disorder
11/20/2003US20030215519 Preferential plugging of vascular sytems of mammals using microstructure particles comprising hydrolytically degradable crosslinked gels
11/20/2003US20030215412 Induction of hair growth with vascular endothelial growth factor
11/20/2003US20030215395 Cationic amine polymer, cationic peptide or cationic carbohydrate and at least one degradable linker molecule connecting said cationic molecules in a branched arrangement
11/20/2003US20030215393 Porous ultrasound contrast agents prepared by freezing both phases of an oil-in-water suspension and removing the frozen phases by sublimation
11/20/2003US20030215392 Paramagnetic particles that provide improved relaxivity
11/20/2003US20030215391 Fluorescent agents for real-time measurement of organ function
11/20/2003US20030215390 Use of poly-nitroxyl-functionalized dendrimers as contrast enhancing agent in mri imaging of joints
11/20/2003US20030215389 Methods for detecting vasculopathies and tumors
11/20/2003DE10209018C1 Perfluoralkylgruppenhaltige micellenbildende Trijodaromaten, Verfahren zu deren Herstellung und deren Verwendung als Kontrastmittel sowie diese enthaltende diagnostische Mittel Perfluoroalkyl Trijodaromaten micelle-forming, processes for their preparation and their use as contrast agents, and diagnostic agents containing this
11/20/2003CA2523888A1 Transgenic rat and the use thereof in the animal model for human huntingdon's disease and nuclear constructs, vectors and cells for the production thereof
11/20/2003CA2485291A1 Mr-signal emitting coatings
11/20/2003CA2451081A1 Adenosine a<sb>3</sb> receptor modulators
11/19/2003EP1362868A2 Humanized and chimeric monoclonal antibodies that bind epidermal growth factor receptor (EGF-R)
11/19/2003EP1206286B1 Method of admixing a gas-containing contrast agent with a flushing medium prior to administration by continuous infusion
11/19/2003EP1019094B1 Contrast-enhanced diagnostic imaging method for monitoring interventional therapies
11/19/2003EP0733066B1 Pretargeting methods and compounds
1 ... 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 ... 354